Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 4Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 4Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

Specimen Handling 483pembrolizumab 456Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 315Biopsy 274Cisplatin 270Radiotherapy 244Paclitaxel 229Gemcitabine 226Bevacizumab 214Nivolumab 189fludarabine 184venetoclax 174Drug Therapy 171Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 145Docetaxel 144Radiosurgery 137Standard of Care 136Rituximab 126Pemetrexed 117durvalumab 115atezolizumab 110Leucovorin 110Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × ravulizumab × 1 year × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔